Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

Can Governance-by-Design Make AI Compliant in Pharma? (Part II)

ByBrian Drapeau

July 16th 2026

Topical Corticosteroid Bioequivalence Guidance Ends 30-Year Wait

The Implications of the FDA’s New Finalized Guidance Documents

ByZachary Zubulake

July 16th 2026

FDA concept. Concept of the Food and Drug Administration. Magnifier glass, folder and clock | Image credit: © Sviatlana - © Sviatlana-stock.adobe.com

Using Risk-Based Quality Frameworks to Fast-Track Biopharma Development: A Q&A with Abzena’s Jeffrey C. Mocny and Cellares’ Anna McMahon

ByFeliza Mirasol,Jeffrey C. Mocny,Anna McMahon

July 15th 2026

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | © Tada Images - stock.adobe.com (521699065)

FDA Activity Round Up – July 2026

ByZachary Zubulake

July 15th 2026

test tube ampoule syringe flag europe doctor vaccine medicine | Image Credit: ©NataliAlba -stock.adobe.com

EMA and EU Innovation Agency Deepen Ties to Speed Up Drug Development

BySusan Haigney

July 15th 2026

Validation Basics: A System Developer's Approach to Validation

Articles in this issue

Related Content

Can Governance-by-Design Make AI Compliant in Pharma? (Part II)

The Implications of the FDA’s New Finalized Guidance Documents

Using Risk-Based Quality Frameworks to Fast-Track Biopharma Development: A Q&A with Abzena’s Jeffrey C. Mocny and Cellares’ Anna McMahon

FDA Activity Round Up – July 2026

EMA and EU Innovation Agency Deepen Ties to Speed Up Drug Development

Trending on Pharmaceutical Technology

FDA Activity Round Up – July 2026

EMA and EU Innovation Agency Deepen Ties to Speed Up Drug Development

Manufacturing Intelligence: Sizing Up Pharma's Biggest AI Deals, Part One

Can Governance-by-Design Make AI Compliant in Pharma? (Part II)

Hidden Cost Drivers in Oligonucleotide Manufacturing